NOVOB80 Stock Price and Chart — SET:NOVOB80

Key facts today

Novo Nordisk's Rybelsus, an oral diabetes drug, showed a 14% lower risk of heart-related death, heart attack, or stroke in a trial with 9,650 patients over four years.

Analyst Abhishek Raval calls Novo Nordisk a strong buy, citing its obesity market leadership. Despite recent setbacks, a 16% growth rate is projected from 2024 to 2027.

In 2024, Novo Holdings bought Catalent for $16.5 billion and sold three Catalent plants to Novo Nordisk for $11 billion to boost Wegovy production.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.